Skip to main content

Advertisement

Table 4 Correlation of clinicopathological factors and surgical outcomes of patients with or without postoperative liver infarction

From: Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer?

Factor Liver infarction (+) (n = 8) Liver infarction (−) (n = 23) p value
Age (years) 61.5 (42–78) 65.0 (39–80) 0.428
Gender, male/female 5/3 16/7 1.000
CEA (ng/mL) 4.0 (1.0–14.0) 3.3 (0.7–493.0) 0.519
CA19-9 (U/mL) 401.0 (3.3–16,860.0) 235.5 (0.1–3211.0) 0.075
Tumor size (MDCT) (cm) 5.0 (1.7–10.1) 3.0 (1.7–7.4) 0.021
GDA/PHA contact (MDCT), yes/no 6/2 4/19 0.006
Anomaly, yes/no 3/5 9/14 1.000
Neoadjuvant chemotherapy, yes/no 7/1 17/6 0.642
Preoperative coil embolization, yes/no 7/1 16/7 0.642
Duration since coiling to operation (days) 15.0 (4–87) 22.5 (4–104) 0.203
Operative time (min) 434 (313–584) 298 (175–540) 0.005
Blood loss (g) 2130 (365–5455) 1100 (305–10270) 0.448
Blood trans fusion, yes/no 5/3 12/11 0.698
Portal vein resection, yes/no 7/1 9/14 0.037
Gastrectomy, yes/no 3/5 2/21 0.093
Bile duct resection, yes/no 1/7 0/23 0.258
Postoperative portal vein stenosis, yes/no 5/3 6/17 0.095
GDA/PHA stenosis, yes/no 8/0 3/20 < 0.001
Tumor size (specimen) (cm) 5.6 (2.8–10.0) 4.0 (2.0–6.5) 0.022
Histologic type, well/mod./por./other 3/2/2/1 7/12/2/2 0.505
Lymph node metastasis, yes/no 7/1 17/6 0.642
Arterial invasion, yes/no 5/3 9/14 0.413
Portal vein invasion, yes/no 6/2 15/8 1.000
Perineural invasion, yes/no 7/1 22/1 0.456
Residual tumor status, R0/R1, 2 4/4 9/14 0.689
UICC stage (7th edition), IIA/IIB, III, IV 0/8 6/17 0.298
Morbidity*, C–D I, II/C–D III, IV, V 1/7 9/14 0.222
Pancreatic fistula**, None, grade A/grade b, C 3/5 11/12 0.698
Liver abscess, yes, no 1/7 0/23 0.258
Postoperative hospital stay (days) 47.5 (26–182) 34.0 (16–97) 0.037
  1. All results are shown as median (range) or number
  2. UICC Union for International Cancer Control
  3. *According to Clavien–Dindo (C–D) classification (ver. 2.0)
  4. **According to International Study Group of Pancreatic Surgeons